entertainment -WSS

entertainment

author：comprehensive 2025-10-01 18:23:37 - browse：32635

Christopher Viehbacher on stage at the 2023 STAT Summit. — Biogen CEO Christopher Viehbacher STAT

Two years after a big scientific swing nearly pushed Biogen to the brink, CEO Christopher Viehbacher is embarking on a corporate rethink, one that balances Biogen’s characteristic risky bets with a frank commitment to pragmatism.

Speaking at the STAT Summit in Boston on Thursday, Viehbacher said his Biogen predecessors fell off track through a few unsound investments and an all-or-nothing bet on Aduhelm, the Alzheimer’s disease treatment that became a pharmaceutical cautionary tale. Viehbacher, one year into his tenure at the storied company, said Biogen’s future will rely on taking a more disciplined approach to risk.

“There’s a huge amount of pride inside the company that we go after problems other people don’t,” Viehbacher said, “but at the end of the day you also have to get medicines through the pipeline to benefit patients, and that’s why we’re expanding the aperture of what we’re doing in R&D.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： AstraZeneca challenges Medicare drug negotiation program

leisure time

hotspot

WSS

Congress must reauthorize a committee to support older Americans

Appeals court upholds limits to abortion pill

What AAP's gender

What do new weight loss drugs mean for bariatric surgery?

NYU radiologists take on the challenge of expensive MRI machines

Neuroscience startup Neumora files for IPO

knowledge

entertainment

knowledge

Medical leaders decry Supreme Court decision on affirmative action

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

New air purifier tech could be key to improving indoor air quality

Winners, losers from Medicare’s list of drugs subject to price talks

Affirmative action in medical school literally saved lives

Surge of respiratory disease in China has likely explanation

In Memoriam: Notable people who died in 2023

Winners, losers from Medicare’s list of drugs subject to price talks

Supreme Court strikes down use of affirmative action

Does good food count as health care? Study aims to find out

knowledge

What do new weight loss drugs mean for bariatric surgery?

AstraZeneca bets AAV gene therapy will still deliver the goods

FDA panel gives mixed vote on blood pressure devices

Complete sequence of Y chromosome published for first time

David Sabatini, ex

NYU radiologists take on the challenge of expensive MRI machines

leisure time

hotspot

explore

focus